Ruiz, et al. reported a loss of neutralizing activity in BAL collected during the later stages of COVID-19 from patients who did not survive, despite the persistence of S1-, RBD-, S2-, and NP-specific IgG and S1-specific IgA after SARS-CoV-2 had been cleared from the lungs [15]. Here, CD79A is linked to COVID-19.